UOC
XFOR icon

UBS O'Connor’s X4 Pharmaceuticals XFOR Stock Holding History

UBS O'Connor’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-80,000
Closed -$152K – 458
2025
Q2 		$152K Buy
80,000
+71,580
+850% +$293K ﹤0.01% 302
2025
Q1 		$59.6K Sell
8,420
-33,725
-80% -$465K ﹤0.01% 278
2024
Q4 		$928K Sell
42,145
-9,500
-18% -$151K 0.02% 236
2024
Q3 		$1.04M Buy
51,645
+12,961
+34% +$270K 0.03% 274
2024
Q2 		$673K Sell
38,684
-5,833
-13% -$191K 0.02% 348
2024
Q1 		$1.86M Sell
44,517
-13,584
-23% -$378K 0.05% 186
2023
Q4 		$1.46M Buy
58,101
+6,101
+12% +$148K 0.05% 221
2023
Q3 		$1.7M Buy
52,000
+37,000
+247% +$1.61M 0.03% 264
2023
Q2 		$873K Buy
+15,000
New +$771K 0.02% 396

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS O'Connor's XFOR Position: Q3 2025 in Review

UBS O'Connor sold out of X4 Pharmaceuticals (XFOR) in Q3 2025, closing a stake of 80,000 shares — an estimated $152K sold.

UBS O'Connor first reported a position in XFOR in Q2 2023 and held it in 9 quarters. The position peaked at $1.86M in Q1 2024. 42 funds tracked by Wall St. Rank hold XFOR as of Q3 2025.

  • UBS O'Connor reported no remaining X4 Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 80,000 X4 Pharmaceuticals shares in Q3 2025, an estimated $152K.
  • UBS O'Connor first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 9 quarters.
  • UBS O'Connor's X4 Pharmaceuticals position peaked at $1.86M in Q1 2024.
  • 42 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.